Clinical trials: Relapsers
Hepatitis C, Genotype 3
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with…
- Conditions
- Hepatitis C, Genotype 3, Non-responders, Relapsers
- Trial name
- NCT00538811
- Testing
- interferon alpha-2b, ribavirin, interferon-gamma,, interferon alpha-2b, ribavirin, amantadine
- Where
- 2 sites in Pakistan
- Volunteers
- 40 people
- Sponsor
- Aga Khan University
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Hepatitis C Infection, HIV Infection
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Background: Chronic hepatitis C (CHC) is a major health problem that particularly affects individuals with human immunodeficiency virus (HIV) infection, and can lead to cirrhosis and liver failure.
- Trial name
- NCT01185028
- Testing
- Nitazoxanide With Pegylated Interferon And Ribavirin
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis C Virus Infection
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subject.
- Trial name
- NCT01718145
- Testing
- Daclatasvir, Asunaprevir, Ribavirin
- Where
- 48 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin
Genotype 1 hepatitis C virus (HCV) patients who did not respond (did not lose virus during treatment) or relapsed (virus went away on treatment but came back after treatment was stopped) after treatment with at least twelve weeks…
- Trial name
- NCT00207402
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Brooke Army Medical Center
Chronic Hepatitis C, HIV Infections
Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies
To determine the efficacy and safety of Peginterferón alfa-2a (40 KD) plus Ribavirin in patients who have relapsed or not responded to a previous suboptimal therapy based in Interferon.
- Trial name
- PILOT-NR (NCT00530972)
- Testing
- Peginterferon alfa-2a plus ribavirin adjusted to body weight
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Carlos III, Madrid
Chronic Hepatitis C, Genotype 1
Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers
This is a non-randomized, open-label study examining the safety and efficacy of betaine in addition to standard anti-viral therapy in genotype 1 hepatitis C non-responders or relapsers to previous pegylated interferon plus…
- Conditions
- Chronic Hepatitis C, Genotype 1, Relapse
- Trial name
- NCT00882193
- Testing
- Betaine, Peginterferon alpha 2a, Ribavirin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Hepatitis C
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis…
- Trial name
- NCT00128271
- Testing
- Bavituximab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Peregrine Pharmaceuticals
Hepatitis C
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
The purpose of this study is to determine if treatment with Pegylated Interferon Lambda-1a, given in combination with Ribavirin and Daclatasvir for 24 weeks, is as safe and effective as the standard treatment with Pegylated…
- Trial name
- STRUCTURE (NCT01718158)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 444 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
- Trial name
- MAGNITUDE (NCT01741545)
- Testing
- Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 71 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C Virus Infection
Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers
The study will be a randomized, double blind, placebo controlled, dose rising study in Interferon alpha (IFN-alpha) non-responder HCV infected patients or HCV patients who have relapsed following IFN-alpha therapy.
- Trial name
- NCT00255359
- Testing
- XTL-2125
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Chronic Hepatitis C
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
SCV-07 (γ-D-glutamyl-L-tryptophan) is a new immunomodulatory compound that has been developed and patented both for composition and immunomodulatory use and is a synthetic dipeptide.
- Trial name
- NCT00968357
- Testing
- SCV-07
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- SciClone Pharmaceuticals
Cardiovascular Diseases, Heart Diseases
Recycling Attempters and Relapsers in Smoking Cessation
To study the process of recycling failed smoking cessation attempts and relapses.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Lung Diseases
- Trial name
- NCT00005687
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Hepatitis C
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with…
- Trial name
- NCT01310205
- Testing
- SCV-07
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- SciClone Pharmaceuticals
Chronic Hepatitis C
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the efficacy of PEG-IFNα-2a + ribavirin…
- Trial name
- NCT01517308
- Testing
- pegylated interferon alpha 2a + ribavirin
- Where
- Italy
- Sponsor
- Federico II University